Literature DB >> 10456922

Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.

A H Tu1, R L Fulgham, M A McCrory, D E Briles, A J Szalai.   

Abstract

Pneumococcal surface protein A (PspA) is a surface-exposed protein virulence factor for Streptococcus pneumoniae. In this study, no significant depletion of serum complement was observed for the serum of mice infected with pneumococci that express PspA. In contrast, in mice infected with an isogenic strain of pneumococci lacking PspA, significant activation of serum complement was detected within 30 min after infection. Also, the PspA-deficient strain but not the PspA-expressing strain was cleared from the blood within 6 h. The contribution of PspA to pneumococcal virulence was further investigated by using mice deficient for C5, C3, or factor B. In mice deficient for C3 or factor B, PspA-negative pneumococci became fully virulent. In contrast, in C5-deficient mice as in wild-type mice, PspA-deficient pneumococci were avirulent. These in vivo data suggest that, in nonimmune mice infected with pneumococci, PspA interferes with complement-dependent host defense mechanisms mediated by factor B. Immunoblots of pneumococci opsonized in vitro suggested that more C3b was deposited on PspA-negative than on PspA-positive pneumococci. This was observed with and without anticapsular antibody. Furthermore, processing of the alpha chain of C3b was reduced in the presence of PspA. We propose that PspA exerts its virulence function by interfering with deposition of C3b onto pneumococci and/or by inhibiting formation of a fully functional alternative pathway C3 convertase. By blocking recruitment of the alternative pathway, PspA reduces the amount of C3b deposited onto pneumococci, thereby reducing the effectiveness of complement receptor-mediated pathways of clearance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456922      PMCID: PMC96800     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene.

Authors:  J Yother; G L Handsome; D E Briles
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

Review 2.  Pneumococcal polysaccharide vaccine.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1989-02-10       Impact factor: 17.586

3.  Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae.

Authors:  M J Crain; W D Waltman; J S Turner; J Yother; D F Talkington; L S McDaniel; B M Gray; D E Briles
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.

Authors:  D E Briles; C Forman; J C Horowitz; J E Volanakis; W H Benjamin; L S McDaniel; J Eldridge; J Brooks
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

5.  Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection.

Authors:  J J Farley; J C King; P Nair; S E Hines; R L Tressler; P E Vink
Journal:  J Pediatr       Date:  1994-06       Impact factor: 4.406

6.  Solid phase enzyme immunoassays for the quantification of serum amyloid P (SAP) and complement component 3 (C3) proteins in acute-phase mouse sera.

Authors:  Y S Taktak; B Stenning
Journal:  Horm Metab Res       Date:  1992-08       Impact factor: 2.936

7.  Analysis of C3 deposition and degradation on bacterial surfaces after opsonization.

Authors:  D L Gordon; J Rice; J J Finlay-Jones; P J McDonald; M K Hostetter
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

8.  Identification of the IgA-binding region in streptococcal protein Arp.

Authors:  E Johnsson; G Andersson; G Lindahl; L O Hedén
Journal:  J Immunol       Date:  1994-10-15       Impact factor: 5.422

9.  Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon.

Authors:  R A Wetsel; D T Fleischer; D L Haviland
Journal:  J Biol Chem       Date:  1990-02-15       Impact factor: 5.157

10.  Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA).

Authors:  L S McDaniel; J Yother; M Vijayakumar; L McGarry; W R Guild; D E Briles
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

View more
  126 in total

1.  The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses.

Authors:  K Overweg; A Kerr; M Sluijter; M H Jackson; T J Mitchell; A P de Jong; R de Groot; P W Hermans
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Contribution of choline-binding proteins to cell surface properties of Streptococcus pneumoniae.

Authors:  Edwin Swiatlo; Franklin R Champlin; Steven C Holman; W William Wilson; James M Watt
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

4.  Role of novel choline binding proteins in virulence of Streptococcus pneumoniae.

Authors:  K K Gosink; E R Mann; C Guglielmo; E I Tuomanen; H R Masure
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades.

Authors:  Eliane N Miyaji; Daniela M Ferreira; Alexandre P Y Lopes; M Cristina C Brandileone; Waldely O Dias; Luciana C C Leite
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

6.  Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.

Authors:  Melanie Abeyta; Gail G Hardy; Janet Yother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

7.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

8.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

9.  Effect of apolactoferrin on experimental pneumococcal otitis media.

Authors:  Patricia A Schachern; Vladimir Tsuprun; Sebahatin Cureoglu; Patricia A Ferrieri; David E Briles; Michael M Paparella; Steven K Juhn
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-11

10.  Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.

Authors:  Bing Ren; Alexander J Szalai; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.